These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 1293723)

  • 21. In vitro and in vivo activity of a palladacycle complex on Leishmania (Leishmania) amazonensis.
    Paladi Cde S; Pimentel IA; Katz S; Cunha RL; Judice WA; Caires AC; Barbiéri CL
    PLoS Negl Trop Dis; 2012; 6(5):e1626. PubMed ID: 22616018
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Leishmania amazonensis: effects of oral treatment with copaiba oil in mice.
    dos Santos AO; Costa MA; Ueda-Nakamura T; Dias-Filho BP; da Veiga-Júnior VF; de Souza Lima MM; Nakamura CV
    Exp Parasitol; 2011 Oct; 129(2):145-51. PubMed ID: 21771592
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections.
    Silveira FT; Lainson R; Shaw JJ; De Souza AA; Ishikawa EA; Braga RR
    Trans R Soc Trop Med Hyg; 1991; 85(6):735-8. PubMed ID: 1801340
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro characterization of Leishmania (Viannia) braziliensis isolates from patients with different responses to Glucantime(®) treatment from Northwest Paraná, Brazil.
    Fernandes AC; Pedroso RB; de Mello TF; Donatti L; Venazzi EA; Demarchi IG; Aristides SM; Lonardoni MV; Silveira TG
    Exp Parasitol; 2016 Aug; 167():83-93. PubMed ID: 27181585
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
    Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
    Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Glucantime reduces mechanical hyperalgesia in cutaneous leishmaniasis and complete Freund's adjuvant models of chronic inflammatory pain.
    da Silva SS; Mizokami SS; Fanti JR; Costa IN; Bordignon J; Felipe I; Pavanelli WR; Verri WA; Conchon Costa I
    J Pharm Pharmacol; 2018 Jun; 70(6):768-777. PubMed ID: 29532470
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antifungal compound butenafine eliminates promastigote and amastigote forms of Leishmania (Leishmania) amazonensis and Leishmania (Viannia) braziliensis.
    Bezerra-Souza A; Yamamoto ES; Laurenti MD; Ribeiro SP; Passero LF
    Parasitol Int; 2016 Dec; 65(6 Pt A):702-707. PubMed ID: 27546158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glucantime efficacy in the treatment of zoonotic cutaneous leishmaniasis.
    Pourmohammadi B; Motazedian MH; Handjani F; Hatam GH; Habibi S; Sarkari B
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):502-8. PubMed ID: 21706927
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of the local or oral delivery of the novel naphthopterocarpanquinone LQB-118 against cutaneous leishmaniasis.
    da Cunha-Júnior EF; Pacienza-Lima W; Ribeiro GA; Netto CD; do Canto-Cavalheiro MM; da Silva AJ; Costa PR; Rossi-Bergmann B; Torres-Santos EC
    J Antimicrob Chemother; 2011 Jul; 66(7):1555-9. PubMed ID: 21531758
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Potential utility of hyperbaric oxygen therapy and propolis in enhancing the leishmanicidal activity of glucantime.
    Ayres DC; Fedele TA; Marcucci MC; Giorgio S
    Rev Inst Med Trop Sao Paulo; 2011; 53(6):329-34. PubMed ID: 22183457
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The activity of azithromycin against Leishmania (Viannia) braziliensis and Leishmania (Leishmania) amazonensis in the golden hamster model.
    Sinagra A; Luna C; Abraham D; Iannella Mdel C; Riarte A; Krolewiecki AJ
    Rev Soc Bras Med Trop; 2007; 40(6):627-30. PubMed ID: 18200413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of azithromycin versus systemic meglumine antimoniate (Glucantime) in the treatment of cutaneous leishmaniasis.
    Layegh P; Yazdanpanah MJ; Vosugh EM; Pezeshkpoor F; Shakeri MT; Moghiman T
    Am J Trop Med Hyg; 2007 Jul; 77(1):99-101. PubMed ID: 17620637
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epoxy-α-lapachone has in vitro and in vivo anti-leishmania (Leishmania) amazonensis effects and inhibits serine proteinase activity in this parasite.
    Souza-Silva F; Bourguignon SC; Pereira BA; Côrtes LM; de Oliveira LF; Henriques-Pons A; Finkelstein LC; Ferreira VF; Carneiro PF; de Pinho RT; Caffarena ER; Alves CR
    Antimicrob Agents Chemother; 2015 Apr; 59(4):1910-8. PubMed ID: 25583728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters].
    Rezzano S; Armas JA; Moreno G; Scorza JV
    Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698
    [No Abstract]   [Full Text] [Related]  

  • 35. Influence of long-term treatment with pravastatin on the survival, evolution of cutaneous lesion and weight of animals infected by Leishmania amazonensis.
    Kückelhaus CS; Kückelhaus SA; Muniz-Junqueira MI
    Exp Parasitol; 2011 Mar; 127(3):658-64. PubMed ID: 21176775
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vivo activity of perifosine against Leishmania amazonensis.
    Cabrera-Serra MG; Valladares B; Piñero JE
    Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy with Imiquimod increases the efficacy of Glucantime therapy of Leishmania major infection.
    Khalili G; Dobakhti F; Mahmoudzadeh-Niknam H; Khaze V; Partovi F
    Iran J Immunol; 2011 Mar; 8(1):45-51. PubMed ID: 21427495
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen as a potential antileishmanial agent: efficacy in the treatment of Leishmania braziliensis and Leishmania chagasi infections.
    Miguel DC; Zauli-Nascimento RC; Yokoyama-Yasunaka JK; Katz S; Barbiéri CL; Uliana SR
    J Antimicrob Chemother; 2009 Feb; 63(2):365-8. PubMed ID: 19095684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of topical liposomes containing meglumine antimoniate (Glucantime) for the treatment of L. major lesion in BALB/c mice.
    Kalat SA; Khamesipour A; Bavarsad N; Fallah M; Khashayarmanesh Z; Feizi E; Neghabi K; Abbasi A; Jaafari MR
    Exp Parasitol; 2014 Aug; 143():5-10. PubMed ID: 24780938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis.
    Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A
    J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.